帕金森病：美舒麦角与溴隐亭的比较

Parkinson's disease: a comparison of mesulergine and bromocriptine.

作者信息

Burton K, Larsen T A, Robinson R G, Bratty P J, Martin W R, Schulzer M, Calne D B

出版信息

Neurology. 1985 Aug;35(8):1205-8. doi: 10.1212/wnl.35.8.1205.

DOI:10.1212/wnl.35.8.1205

Abstract

Previous studies with mesulergine (CU 32-085) demonstrated safety and efficacy in short-term observations of patients with Parkinson's disease. We compared mesulergine with bromocriptine in 20 patients with Parkinson's disease. Eighteen patients completed the randomized, double-blind, crossover study. Clinical assessments employed the UBC scale and "Mini-Mental State" examination; neurophysiologic measurements were undertaken on wrist rigidity and speed and accuracy of hand movement, and toxicity screening tests were compared. There were no significant differences between the effects of mesulergine (mean dosage, 27.4 mg/d) and bromocriptine (mean dosage, 40.8 mg/d).

摘要

先前对美舒麦角（CU 32 - 085）的研究在帕金森病患者的短期观察中证明了其安全性和有效性。我们将20例帕金森病患者的美舒麦角与溴隐亭进行了比较。18例患者完成了随机、双盲、交叉研究。临床评估采用UBC量表和“简易精神状态”检查；对腕部僵硬以及手部运动的速度和准确性进行了神经生理学测量，并比较了毒性筛查测试。美舒麦角（平均剂量，27.4毫克/天）和溴隐亭（平均剂量，40.8毫克/天）的效果之间没有显著差异。